Janssen Pharmaceutica Nv

Araxes Pharma LLC

Brett D Allison

Michael D Hack

Cheryl A Grice

Michael H Rabinowitz

Victor K Phuong

Hariharan Venkatesan

Michael Anthony Letavic

Laurent Gomez

John J M Wiener

Kimberly Schwarz

Alejandro Santillán, Jr

Liu Y Tang

James Patrick Edwards

Peter J Connolly

Tianbao Lu

Neelakandha S Mani

J Guy Breitenbucher

Kevin Douglas Kreutter

Maxwell David Cummings

Tongfei Wu

Alec D Lebsack

Natalie Anne Hawryluk

Didier Jean-Claude Berthelot

Xiaohu Deng

Gaston S Diels

Kelly J McClure

Mark D Rosen

Bryan James Branstetter

Joseph Kent Barbay

Jimmy T Liang

Jeffrey E Merit

Karen Joy Shaw

Ulrike Philippar

Nigel P Shankley

Johannes Wilhelmus John Fitzgerald Thuring

Fang Shen

Brian J Morrow

S Timothy Motley

Marna C W Pippel

Pingda Ren

Liansheng Li

Curt A Dvorak

Nicholas I Carruthers

Yun Long

Heather Renee Coate

Brad M Savall

Devin M Swanson

Yuan Liu

John M Keith

Christine Fang Gelin

Christa C Chrovian

Brice M Stenne

Akinola Soyode-Johnson

Emily M Stocking

Jason Christopher Rech

James Breitenbucher

Michael P Curtis

Manuel Jesus Alcazar Vaca

Jose Ignacio Andres Gil

Jessica L Wall

Meri De Angelis

Zachary S Sales

Laura C McAtee

Laura C McAfee

Jennifer M B Miller

Kelly J Mcclure

Natalie A Hawryluk

Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R, R, R, R, R, R, R, G, and Gare defined herein.

Pyrazole derivatives as MALT1 inhibitors

The present invention is directed to compounds of Formulas (I, Ia, IIa and IIb). The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, Ia, IIa and IIb). Methods of making and using the compounds of Formulas (I, Ia, IIa and IIb) are also within the scope of the invention. 

P2X7 modulators and methods of use

Methods for preparing compounds having the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein R, R, R, R, R, R, Rand R, are as defined herein are provided. Related compounds and methods for making the same are also provided.

Methods for preparation of quinazoline derivatives

Certain tetrahydro-pyrimidoazepine compounds are described, which are useful as TRPV1 modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by TRPV1. Thus, the compounds may be administered to treat, e.g., pain, itch, cough, asthma, or inflammatory bowel disease.

Tetrahydro-pyrimidoazepines as modulators of TRPV1

Antibacterial compounds, compositions containing them, and methods of use for the inhibition of bacterial activity and the treatment, prevention or inhibition of bacterial infection.

Bicyclic pyrazole compounds as antibacterial agents

Certain cyclopropyl amines are histamine Hmodulators useful in the treatment of histamine Hreceptor mediated diseases.

[object Object]

Certain sulfonamide compounds are dual CCK1/CCK2 inhibitors useful in the treatment of CCK1/CCK2 mediated diseases.

Sulfonamide compounds

Certain amidophenyl-sulfonylamino-quinoxaline compounds are CCK2 modulators useful in the treatment of CCK2 mediated diseases.

Quinoxaline compounds

Certain amidophenyl-sulfanylamino-benzo[1,2,5]thiadiazole compounds are CCK2 modulators useful in the treatment of CCK2 mediated diseases.

Benzo[1,2,5]thiadiazole compounds

Certain substituted benzyl amine compounds are histamine Hreceptor and/or serotonin transporter modulators useful in the treatment of histamine Hreceptor- and/or serotonin-mediated diseases.

Substituted benzyl amine compounds

Growing community of inventors

Del Mar, CA, United States of America

Brett D Allison